Sanofi Consumer Healthcare
5,185.40
+88.00(+1.73%)
Market Cap₹11,942.30 Cr
PE Ratio60.30
IndustryHealthcare
Company Performance:
1D+1.73%
1M+3.69%
6M+13.90%
1Y+5.75%
5Y+5.75%
View Company Insightsright
Latest news about Sanofi Consumer Healthcare
Sanofi Consumer Healthcare India Appoints New CFO Amid Strong Q2 Performance Aug 04, 2025
Sanofi Consumer Healthcare India has appointed Mr. Narahari Naidu as CFO effective August 4th, 2025. The company reported impressive Q2 2025 results with revenue at ₹2,209.00 million, up 28.21% YoY, and net profit at ₹607.00 million, a 109.31% increase from Q2 2024. The company successfully relaunched Depura Adult and Combiflam Suspension, contributing to strong performance. An exceptional gain of ₹66.00 million was recorded from reversing excess demerger-related provisions.
Sanofi Consumer Healthcare India Reports Strong Q1 Results with 28% Revenue Growth Aug 04, 2025
Sanofi Consumer Healthcare India Reports Mixed Q4 Results Amid Product Recalls May 02, 2025
Sanofi Consumer Healthcare Faces Potential 26% Stake Acquisition by Opal Bidco Sas and Clayton, Dubilier & Rice Fund Apr 25, 2025
Opal Bidco SAS Proposes 26% Stake Acquisition in Sanofi Consumer Healthcare India Apr 24, 2025
More news about Sanofi Consumer Healthcare
20Feb 25
Sanofi Consumer Healthcare Declares ₹55 Dividend, Reports Strong FY2024 Performance
Sanofi Consumer Healthcare India Limited (SCHIL) has declared a final dividend of ₹55 per equity share for FY2024, subject to shareholder approval. The company reported total income of ₹7,375 million and net profit of ₹1,810 million for the year ended December 31, 2024. Revenue from operations grew by 30.4% to ₹7,245 million. SCHIL completed its demerger from Sanofi India Limited and listed on NSE and BSE in September 2024. The company voluntarily recalled Allegra and Combiflam Suspensions in July 2024 as a precautionary measure.
20Feb 25
Sanofi Consumer Healthcare: Q4 Profit Drops 35%, Declares ₹55 Dividend
Sanofi Consumer Healthcare India Limited (SCHIL) reported a significant downturn in its Q4 2024 financial results. Revenue decreased by 24% to ₹170.7 crore, while net profit fell by 34.8% to ₹44.3 crore compared to Q4 2023. EBITDA also declined by 30.6% to ₹61.1 crore, with margins contracting to 36.4%. Despite the challenging quarter, the company declared a final dividend of ₹55 per share for FY2024, subject to shareholder approval.
Sanofi Consumer Healthcare
5,185.40
+88.00
(+1.73%)
1 Year Returns:+5.75%
Industry Peers
Sun Pharmaceutical
1,594.50
(+0.55%)
Divis Laboratories
6,131.50
(-0.01%)
Cipla
1,589.40
(+0.58%)
Torrent Pharmaceuticals
3,559.80
(-0.48%)
Dr Reddys Laboratories
1,260.10
(+0.02%)
Mankind Pharma
2,471.40
(-0.11%)
Zydus Life Science
981.05
(+0.25%)
Lupin
1,894.90
(-0.39%)
Abbott
31,480.00
(+0.02%)
Alkem Laboratories
5,303.50
(-1.35%)